ConsumerLab.com uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.

About ConsumerLab.com

Posted January 12, 2021

Infuscience, Inc. Warned for Unsanitary Production Practices

On December 21, 2020, the FDA issued a warning letter to Infuscience, Inc. dba Bioscrip Infusion Services following a facility inspection in July, 2019 which found the company's products to be drugs, and therefore, adulterated because they were prepared, packed, or held under conditions that violate Current Good Manufacturing Practices for dietary supplements.

These violations include preparing products that were intended or expected to be sterile under unsanitary conditions as required by federal regulations. Employees failed to disinfect and change gloves to prevent contamination, the company did not perform adequate air ventilation studies, drugs were produced without cleaning work surfaces and instruments, and certain surfaces were visibly dirty, among other sanitary violations.

Infuscience, Inc. dba Bioscrip Infusion Services must amend their production practices and inform the FDA within 15 days of the specific steps they are taking to fix these violations.

For more information, use the link below.

Warning Letter: Infuscience, Inc. dba Bioscrip Infusion Services

See related warnings:

Bulletproof Warned for Manufacturing Violations

Seller of CoQ10, Resveratrol and More Warned for Manufacturing Violations

Seller of Digestion Supplements Warned for Manufacturing Violations

Seller of Tea, Colloidal Silver, Homeopathic Products Warned for Manufacturing Violations

Seller of Liposomal Curcumin, Vitamin C & Melatonin Warned for Manufacturing Violations